Deals in Depth: April 2009
Executive Summary
Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries includes these highlights from February 2009: Pharmaceutical alliance money was weak: the biggest deal of the month was Novartis' $150mm license to Portola's Phase II cardio candidate elinogrel. In M&A, Lundbeck was on top with its takeover of spec pharma Ovation, expanding the European company's neurology drug portfolio in the US. Meanwhile, Beckman Coulter improved its position in the chemistry testing market by buying Olympus' diagnostic systems unit. And Medtronic made two major cardiovascular acquisitions: Ventor and CoreValve. Finally, pharmaceutical financing tripled three times since January to $1.6bn thanks to more than $1bn in public offerings including $684mm netted by BMS, which sold 15% of Mead Johnson through an IPO--the first in the Rx space in one year--as well as Vertex's $314mm FOPO.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.